Returning for its 15th year SMi presents UK鈥檚 premier pain event, the 15th Annual Pain Therapeutics taking place on 18-19 May 2015 in London, UK. Through a series of interactive presentations and panel discussions, this event provides access to key industry leaders, spotlighting principles and illustrative examples on current activities and trends in clinical and pre-clinical evidence-based and best-practice-based pain medicine.
Benefits of attending:
鈥� New for 2015 - Presentations on personalized medicine for pain, biomarkers and CGRP receptor antagonists for migraine treatment
鈥� Learn about Grunenthal鈥檚 latest screening approach for neuropathic pain and pain models
鈥� Hear timely case studies from Merck and Afferent Pharmaceuticals
鈥� Spotlight sessions - Latest updates on developments in targeting nerve growth factors
鈥� Discover latest advances in the treatment of pain from leading, pharma, biotech and academic experts from the industry
鈥� Interactive panel discussion the reviewing validity of animal models for chronic pain
Key speakers include:
鈥� Professor Anthony Jones, Professor of Neuro-Rheumatology, Human Pain Research Group, University of Manchester
鈥� Professor Richard Knowles, CEO, Arachos Pharma
鈥� Dr Emanuele Sher, Senior Research Advisor, Neuroscience, Discovery, Lilly Research Centre, Eli Lilly
鈥� Dr Anthony P. Ford, Chief Scientific Officer, Afferent Pharmaceuticals
鈥� Dr Richard Butt, Senior Director, Research Project Leader, Clinical Research, Pfizer
鈥� Dr Shahnaz Yusaf, Investigator Biopharm Innovation BDU, GlaxoSmithKline
鈥� Dr Ian Bell, Principal Scientist, Discovery Chemistry, Merck
鈥� Dr Mark T. Brown, MD, Executive Director, Clinical Program Leader for Osteoarthritis and Cancer Pain Studies, Pfizer Inc
鈥� Dr Gregor Bahrenberg, Associate Scientific Director, Grunenthal
In addition, don鈥檛 miss the two interactive post conference workshops taking place on the 20th May:
鈥� Healthcare Innovation - A patient centred approach
Hosted by: Insight Consultancy
鈥� In vitro techniques and models for pain drug development:鈥淐linical trial in a dish鈥�
Hosted by: Imperial College London
Benefits of attending:
鈥� New for 2015 - Presentations on personalized medicine for pain, biomarkers and CGRP receptor antagonists for migraine treatment
鈥� Learn about Grunenthal鈥檚 latest screening approach for neuropathic pain and pain models
鈥� Hear timely case studies from Merck and Afferent Pharmaceuticals
鈥� Spotlight sessions - Latest updates on developments in targeting nerve growth factors
鈥� Discover latest advances in the treatment of pain from leading, pharma, biotech and academic experts from the industry
鈥� Interactive panel discussion the reviewing validity of animal models for chronic pain
Key speakers include:
鈥� Professor Anthony Jones, Professor of Neuro-Rheumatology, Human Pain Research Group, University of Manchester
鈥� Professor Richard Knowles, CEO, Arachos Pharma
鈥� Dr Emanuele Sher, Senior Research Advisor, Neuroscience, Discovery, Lilly Research Centre, Eli Lilly
鈥� Dr Anthony P. Ford, Chief Scientific Officer, Afferent Pharmaceuticals
鈥� Dr Richard Butt, Senior Director, Research Project Leader, Clinical Research, Pfizer
鈥� Dr Shahnaz Yusaf, Investigator Biopharm Innovation BDU, GlaxoSmithKline
鈥� Dr Ian Bell, Principal Scientist, Discovery Chemistry, Merck
鈥� Dr Mark T. Brown, MD, Executive Director, Clinical Program Leader for Osteoarthritis and Cancer Pain Studies, Pfizer Inc
鈥� Dr Gregor Bahrenberg, Associate Scientific Director, Grunenthal
In addition, don鈥檛 miss the two interactive post conference workshops taking place on the 20th May:
鈥� Healthcare Innovation - A patient centred approach
Hosted by: Insight Consultancy
鈥� In vitro techniques and models for pain drug development:鈥淐linical trial in a dish鈥�
Hosted by: Imperial College London
